Significant systemic and CNS activity of RET inhibitor vandetanib combined with mTOR inhibitor everolimus in patients with advanced NSCLC with RET fusion.
Year: 2016
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Tina Cascone, Vivek Subbiah, Kenneth R. Hess, Sarah Nelson, Monique B. Nilsson, Ishwaria Mohan Subbiah, Siraj Mahamed Ali, David Paul Carbone, Ravi Salgia, Taofeek Kunle Owonikoko, Funda Meric-Bernstam, Robert Charles Doebele, John Heymach, *Vivek Subbiah and Tina Cascone Equally contributed to trial
Institutions: The University of Texas MD Anderson Cancer Center, University of Colorado Anschutz, Foundation Medicine (United States), The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, University of Chicago, Emory University, Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2891653057